Assetmark, Inc Immunocore Holdings PLC Transaction History

Assetmark, Inc

$34.9 Billion
Q3 2024

A detailed history of Assetmark, Inc transactions in Immunocore Holdings PLC stock. As of the latest transaction made, Assetmark, Inc holds 30,555 shares of IMCR stock, worth $863,484. This represents 0.0% of its overall portfolio holdings.

Number of Shares

30,555

Previous 28,677 6.55%

Holding current value

$863,484

Previous $971,000 2.06%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	BUY	$30.06 - $41.49 $56,452 - $77,918	1,878 Added 6.55%	30,555 $951,000
Q2 2024 Aug 13, 2024	BUY	$33.78 - $63.75 $237,507 - $448,226	7,031 Added 32.48%	28,677 $971,000
Q1 2024 May 06, 2024	BUY	$60.14 - $75.36 $220,473 - $276,269	3,666 Added 20.39%	21,646 $1.41 Million
Q4 2023 Feb 09, 2024	BUY	$42.85 - $69.5 $298,621 - $484,345	6,969 Added 63.29%	17,980 $1.23 Million
Q3 2023 Oct 27, 2023	BUY	$49.5 - $66.6 $193,149 - $259,873	3,902 Added 54.89%	11,011 $571,000
Q2 2023 Aug 11, 2023	BUY	$48.54 - $61.64 $302,064 - $383,585	6,223 Added 702.37%	7,109 $426,000
Q1 2023 May 05, 2023	BUY	$46.12 - $65.71 $12,821 - $18,267	278 Added 45.72%	886 $43,000
Q4 2022 Feb 10, 2023	BUY	$45.51 - $65.08 $13,516 - $19,328	297 Added 95.5%	608 $34,000
Q3 2022 Nov 01, 2022	BUY	$37.34 - $57.44 $3,435 - $5,284	92 Added 42.01%	311 $15,000
Q2 2022 Aug 03, 2022	BUY	$25.46 - $37.72 $3,182 - $4,715	125 Added 132.98%	219 $8,000
Q1 2022 May 13, 2022	BUY	$18.94 - $34.29 $1,780 - $3,223	94 New	94 $3,000

Others Institutions Holding IMCR

# of Institutions

141

Shares Held

41.4M

Call Options Held

197K

Put Options Held

451K

View Full List

About Immunocore Holdings plc

Ticker IMCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,897,100
Market Cap $1.24B
Description
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...

More about IMCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.

Account